· More than 150,000 deaths from #COVID19 went uncounted in the U.S. in the first two years of the pandemic, a new study in Science Advances finds
· Swiss researchers have found up to 60% of healthcare workers in a medium-size cohort study may have at least one symptom of #LongCOVID
· Small clinical trial recruiting in Orange, CA, to test Percutaneous Electrical Nerve Field Stimulation in children with post-concussion syndrome and LC
https://thesicktimes.org/2026/03/24/research-updates-march-24/
More than 150,000 deaths from COVID-19 went uncounted in the U.S. in the first two years of the pandemic, according to a new study in Science Advances. Researchers used machine learning to evaluate death certificates from March 2020 to December 2021, and estimated that 19% more COVID-19 deaths occurred than originally reported.
· Two recent prevalence studies showed the impact of #LongCOVID on Americans
· A small study shared as a preprint in bioXriv found SARS-C0V-2 spike protein in the gut tissues of people with Long COVID
· Researcher Dianna Arnoux-Whiteman was awarded a $45,000 grant to survey the effects of Long COVID in the Blackfeet Nation
https://thesicktimes.org/2026/03/17/research-updates-march-17/
Two recent prevalence studies showed the impact of Long COVID on Americans. The first, an electronic cohort study of over 600,000 active military personnel, found that 42% had at least one symptom more than 30 days after contracting COVID-19.
· A large retrospective cohort study found significant healthcare cost increases for #LongCOVID over five years
· A South Korean clinical trial evaluated metformin and ursodeoxycholic acid (UDCA) for Long COVID, but didn’t find either effective
· Two recent preprints share additional analysis from clinical trials seeking to address viral persistence
https://thesicktimes.org/2026/03/10/research-updates-march-10/
· Researchers identified high levels of cytokine interferon gamma (IFN-γ) as a potential biomarker for #LongCOVID
· Two new studies compare SARS-CoV-2’s long-term risks to those of the flu
· A small phase 1 clinical trial will test the safety of the cancer monoclonal antibody Pembrolizumab (Keytruda)
https://thesicktimes.org/2026/03/03/research-updates-march-3/
Researchers identified high levels of cytokine interferon gamma (IFN-γ) in white blood cells as a potential biomarker for Long COVID. The small study, published in Science Advances, found that symptoms improved when production of IFN-γ (a molecule that plays an important role in immune response) decreased.
· SARS-CoV-2 reinfections significantly increase the risk of #LongCOVID in children, a new National Institutes of Health (NIH) RECOVER study found
· A large cohort study found further evidence that people with #HIV have a significantly increased risk of Long COVID following SARS-CoV-2 infection
· An in-depth whole genome sequencing study called Sequence #MECFS and Long COVID is seeking to raise £20 million ($23.6 million USD) in funding
https://thesicktimes.org/2026/02/24/research-updates-february-24/
· New review in Dovepress states that #LongCOVID, #MECFS & #POTS should be classified as neuroimmune disorders.
· Wearable activity tracker notifications may not be a reliable way to mitigate or reduce PEM, new study in Nature Communications
· Small, phase one study is recruiting in Sacramento & San Francisco, CA to test advanced techniques in total body imaging to improve understanding of “tissue-level immune dysregulation” in the disease
https://thesicktimes.org/2026/02/17/research-updates-february-17/
· A large study recently connected “chronic absenteeism” to pediatric #LongCOVID, further disproving the “immunity debt” talking points from pundits earlier in the pandemic
· A small mechanistic study in Brain, Behavior, & Immunity – Health found that immunoglobulin G (IgG), isolated from people with #MECFS, can destroy mitochondria in endothelial cells
· ADDRESS-LC has opened two more study sites: a new one in California and one in Connecticut
https://thesicktimes.org/2026/02/10/research-updates-february-10/
· The Food and Drug Administration (FDA) has granted expanded access to the stem cell infusion RegeneCyte for #LongCOVID
· Long COVID isn’t being consistently captured around the world due to differences in sociological factors, diagnostic tools, and healthcare access
· A phase two trial for Long COVID-associated postural orthostatic tachycardia syndrome (#POTS) is testing a product called 2-hydroxybenzylamine (2-HOBA)
https://thesicktimes.org/2026/02/03/research-updates-february-3/
· A large prospective cohort study published in Infectious Diseases found that a majority of people with #LongCOVID did not recover
· Some researchers in Australia are getting a small boost in Long COVID funding
· The biotech company Invivyd is advancing research of a #COVID19 monoclonal antibody called VYD2311, designed to improve upon the currently-available Pemgarda
https://thesicktimes.org/2026/01/27/research-updates-january-27/
· A new study in eBioMedicine found neurological #LongCOVID symptoms were associated with increased pTau-181 levels, a marker of brain inflammation tied to Alzheimer’s disease
· A new “state-of-the-art” review on #POTS highlighted that the multisystemic condition is disabling, causes societal & economic withdrawal
· A phase II clinical trial testing efficacy & safety Uplizna (Inebilizumab) in LC & #MECFS recently announced by German Ministry of Research
https://thesicktimes.org/2026/01/20/research-updates-january-20/
Anti. 🐘
